Endo on hold by Jefferies

Endo Pharmaceuticals Holdings, Inc. was rated at hold by Jefferies & Co., Inc. analyst David Windley on the 10%+ sell-off in Tuesday's aftermarket. This reflects Lidoderm's importance to the company as well as the Food and Drug Administration's surprisingly low generic hurdle, according to the analyst. With the FDA's Office of Generic Drugs providing recommendations on demonstrating bioequivalence to Lidoderm, a potential generic competitor may arrive sooner than expected. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down $4.50, or 13.27%, at $29.41. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.